Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes.

Stefano CiardulloLaura SavaréFederico ReaGianluca PerseghinGiovanni Corrao

Published in: Diabetes/metabolism research and reviews (2024)

Higher adherence to drug treatment with GLP1-RA and SGLT2-I during the first year of the drug intake is associated with a lower incidence of adverse clinical outcomes in a real-world setting.

Keyphrases

rheumatoid arthritis
adverse drug
disease activity
risk factors
ankylosing spondylitis
drug induced
type diabetes
weight gain
combination therapy
metabolic syndrome
adipose tissue
interstitial lung disease
physical activity
electronic health record
insulin resistance